Paolo Tarantino: Very promising activity with a new CDK4i

Paolo Tarantino shared the following post by ESMO on X, adding the following:

“Very promising activity with PF07220060, a new CDK4i. Among 33 pretreated (median: 4) pts, all with prior CDK4/6i, ORR was 32%, DCR 81%, mPFS 8.1 months, with favorable tox profile. The new generation of CDK inhibitors is here: looking forward to randomized data.”

Quoting ESMO’s post:

“Studies at ESMO Breast 24 provide evidence of potential efficacy for a novel CDK4-selective inhibitor and long-lasting benefits for a pan-AKT inhibitor.”

Read further.
Source: Paolo Tarantino/X and ESMO/X

Dr. Paolo Tarantino, MD researcher, holds positions at both the European Institute of Oncology in Milan, Italy, and the Dana-Farber Cancer Institute in Boston, MA, Specializing in breast cancer. Currently, Dr. Tarantino is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.
OncoDaily
His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a robust publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field. Dr. Tarantino’s dedication and innovative approach contribute significantly to the advancement of breast cancer treatment and research.